ClinicalTrials.gg
CompletedNCT04918771Updated Oct 15, 2024Results posted

Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old

A Phase 3 interventional study of Raphamin and Placebo in Acute Respiratory Viral Infection, sponsored by Materia Medica Holding. Completed at 29 sites in Russian Federation. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Materia Medica Holding · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
435
Allocation
Randomized
Ages
12 Years to 18 Years
Sex
All
01

Study summary

The multicenter double-blind placebo-controlled randomized in parallel-group. The objective of this study is to evaluate efficacy and safety of Raphamin in the treatment of acute respiratory viral infection (ARVI) in children aged 12-18 years old.

Read the detailed description

Design: a multicenter, double-blind, placebo-controlled, parallel-group randomized clinical trial.

The study will enroll outpatient subjects of either gender aged 12-18 old years with clinical manifestations of acute respiratory viral infection (ARVI) within the first days after the onset of the disease. The patients will be recruited during seasonal ARVI morbidity. Collection of history, thermometry, objective examination, laboratory tests, recording concomitant therapy will be made after parent/adoptive parent signing information sheet and informed consent form for the child participation in the clinical study, for children ≥14 years old after signing patient information sheet and informed consent form for children ≥14 years old to participate in the clinical study. The severity of ARVI symptoms will be evaluated with a 4-point scale.

The nasopharyngeal swabs for PCR diagnosis and verification of respiratory viruses will be performed prior to therapy to confirm the viral etiology of ARVI. To rule out the infection caused by the new coronavirus COVID-19 (Coronavirus disease 2019), a rapid test for SARS-CoV-2 antigen will be made. In case of a positive SARS-CoV-2 test, the physician will act in accordance with the current version of the RF MoH Temporary methodological recommendations "Prevention, diagnosis, and therapy of new coronavirus infection (COVID-19)".

If a patient meets all inclusion criteria and does not have any exclusion criteria, at Visit 1 (Day 1), he/she will be randomized into one of two groups: patients of group 1 will take Raphamin according to the dosage regimen for 5 days; patients of group 2 will take Placebo using Raphamin 5-day regimen.

The study will use an electronic patient diary (EPD) for recording morning and evening axillary body temperature (using a classic mercury-free thermometer) and disease symptoms (Symptom Severity Score). Besides, antipyretic dosing (if applicable) and any deterioration in a patient's condition (if applicable, for safety evaluation/AE documentation) will also be recorded in a patient diary. The investigator will provide instructions on filling the diary. At Visit 1 the parent/adoptive parent together with an investigator will record ARVI symptom severity and body temperature in the diary.

Patients will be observed for 14 days (screening, randomization - up to 1 day, treatment period - 5 days, follow-up - up to 2 days; deferred "phone visit" - day 14).

During the treatment and follow-up period the patients/physicians will make 3 visits and the fourth "phone visit" will be scheduled additionally: 1) visits by physician/patient - on Days 1, 5, and 7 (Visits 1, 2, and 3) - in a study center or at home; 2) "phone visit" (Visit 4) - on Day 14.

At Visits 2 and 3, the investigator will perform an objective examination, document changes in the symptoms and concomitant medications, and check patient diaries. At Visit 3 laboratory tests will be performed and compliance will be checked.

"Phone visit" will be performed to interview parents/adoptive parents about the patient's condition, presence/absence of secondary bacterial/viral complications, and use of antibiotics.

During the study, symptomatic therapy and therapy for their co-morbidities are allowed with the exception of the drugs indicated in the section "Prohibited Concomitant Treatment".

02

Conditions studied

  • Acute Respiratory Viral Infection
03

In context

Lead sponsor

Materia Medica Holding is the lead sponsor of 43 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients of either gender aged 12 to 18 years.
  2. Diagnosis of ARVI based on medical examination: axillary temperature ≥ 37.8°C at examination + non-specific flu-like symptoms score ≥4, nasal/throat/chest symptom score ≥2.
  3. The first 24 hours after ARVI onset.
  4. measures by sexually active adolescents of both genders during the study.
  5. Patient information sheet ( form) signed by one parent/adoptive parent of the patient and there is also a signed patient information sheet (informed consent form) for children aged 14 and over.

Exclusion criteria

Exclusion Criteria:

  1. Clinical symptoms of severe influenza/ARVI requiring hospitalization.
  2. Positive SARS-CoV-2 (COVID-19/Coronavirusdisease2019) antigen test.
  3. Suspected pneumonia, bacterial infection (including otitis media, sinusitis, urinary tract infection, meningitis, sepsis, etc.) requiring administration of antibiotics from the first day of illness.
  4. Suspected initial manifestations of diseases with symptoms similar to ARVI at onset (other infectious diseases, flu-like syndrome at the onset of systemic connective tissue diseases, and other pathology).
  5. Patients requiring antiviral medication prohibited within the study.
  6. Medical history of primary and secondary immunodeficiency.
  7. Medical history/suspicion of oncology of any localization (except for benign neoplasms).
  8. Aggravation or decompensation of chronic diseases (diabetes mellitus, infantile cerebral paralysis, cystic fibrosis, primary ciliary dyskinesia, bronchopulmonary dysplasia, respiratory and ENT congenital defects, etc.) affecting a patient's ability to participate in the clinical trial.
  9. Malabsorption syndrome, including congenital or acquired lactase or other disaccharidase deficiency, galactosemia.
  10. Allergy/ to any component of the study drugs used in the treatment.
  11. Pregnancy. Breast-feeding.
  12. Use of medications specified in the section "Prohibited Concomitant Therapy" within two weeks prior to inclusion in the study.
  13. Patients whose parents/adopters, from the investigator's point of view, will not comply with the observation requirements during the study or follow the procedure for taking the study drugs.
  14. Medical history of mental diseases of the patient or their parent(s)/adoptive parents.
  15. Participation in other clinical trials for 3 months prior to enrollment in this study.
  16. Patient's parents/adopters who are related to any of the on-site research personnel directly involved in the study or are an immediate relative of the investigator. 'Immediate relative' means husband, wife, parent, son, daughter, brother, or sister (regardless of whether they are natural or adopted).
  17. The patient's parent/adopter who work for OOO "NPF "MATERIA MEDICA HOLDING" (i.e. the company's employees, temporary contract workers, designated officials responsible for carrying out the research or any immediate relatives of the aforementioned).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
435 participants (actual)

Study arms

  • Experimental
    Raphamin

    Tablet for oral use.

    Drug: Raphamin

  • Placebo comparator
    Placebo

    Tablet for oral use.

    Drug: Placebo

Interventions

  • Oral administration - not with food. Keep the tablet in the mouth until it is completely dissolved. On the 1st day of treatment, 8 tablets are taken according to the following scheme: 1 tablet every 30 minutes in the first 2 hours (a total of 5 tablets in 2 hours), then during the same day, take another 1 tablet 3 times at regular intervals. On the 2nd day and then take 1 tablet 3 times a day. The duration of treatment is 5 days.

  • DrugPlacebo

    Oral administration - not with food. Placebo using Raphamin scheme.

06

What researchers measure

Primary outcomes

  1. Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms (ARVI, Confirmed by Polymerase Chain Reaction (PCR)).

    Outcome Measure is evaluated on the basis of ARVI, confirmed by Polymerase chain reaction (PCR), i.e virus detection. ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from "0" to "42". The TSS higher score is the worse outcome.

    Time frame: 14 days of observation

Secondary outcomes

  1. Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed).

    The outcome measure is based on the area under the curve (AUC) for the TSS (Total symptoms score). TSS is calculated as a sum of scores for 14 different symptoms. 13 of them are different ARVI manifestations, each of them is evaluated on a scale: 0 (none), 1 (mild), 2 (moderate), 3 (severe). 14th symptom is body temperature (temp) which is converted to its score using following rules: if temp \<= 37.3 then score = 0 (none) if 37.3 \< temp \<= 38.0 then score = 1 (mild) if 38.0 \< temp \<= 39.0 then score = 2 (moderate) if 39.0 \< temp then score = 3 (severe) So it is 14 symptoms and the score for each of them varies between 0 and 3. Minimum TSS is 0, maximum is 42 (higher TSS score is worse). AUC is calculated for all timepoints available for patient.

    Time frame: Day1 through Day6 of the treatment and observation

  2. Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed).

    ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from "0" to "42". The TSS higher score is the worse outcome.

    Time frame: 14 days of observation

  3. Time to Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed).

    ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from "0" to "42". The TSS higher score is the worse outcome.

    Time frame: 14 days of observation

  4. Percentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed).

    Outcome Measure is based on the Percentage of Patients With Resolution of ARVI, confirmed by Polymerase chain reaction (PCR), i.e virus detection. ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from "0" to "42". The TSS higher score is the worse outcome.

    Time frame: 14 days of observation

  5. Dosing Frequency of Antipyretics.

    Outcome Measure is based on the rates of antipyretic use per patient during days 1 to 3 of therapy according to the electronic patient diary.

    Time frame: 3 days of therapy

  6. Percentage of Patients Reporting Worsening of Illness.

    Outcome Measure is based on the rates of Complications that require the use of antibiotics or hospitalization.

    Time frame: Day 4 through day 14 of the treatment and observation period

  7. Occurrence and Type of Adverse Events (AE) During the Treatment. AE Severity.

    1. The intensity (severity) of adverse events. 2. Causal relationship of AEs to the sudy drug. 3. Outcome of AEs. Based on medical records.

    Time frame: 14 days of observation

  8. Changes in Vital Signs: Pulse Rate/Heart Rate in Beats Per Minute (Bpm).

    The outcome measure is based on the medical records. The patient's heart rate (heart rate) is measured by the physician in every visit (on days 1, 5, and 7).

    Time frame: Day 1 through day 7 of the treatment and observation period.

  9. Changes in Vital Signs: Respiration Rate/Breathing Rate in Breaths Per Minute.

    Outcome Measure is based on the medical records. The patient's respiration rate (breathing rate) is measured by physician in every visit (on days 1, 5, and 7).

    Time frame: Day 1 through day 7 of the treatment and observation period.

  10. Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg).

    Outcome Measure is based on the medical records. The patient's blood pressure is measured by the physician in every visit (on days 1, 5, and 7).

    Time frame: Day 1 through day 7 of the treatment and observation period.

  11. Percentage of Patients With Clinically Relevant Abnormal Laboratory Findings.

    Outcome Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which are beyond the reference values at the end of treatment.

    Time frame: Day 1 through day 7 of the treatment and observation period.

07

Results

Posted Oct 15, 2024

Participant flow

Participant flow — Overall Study
MilestoneRaphaminPlacebo
Started206214
Completed199205
Not completed79
Withdrew: Withdrawal by subject45
Withdrew: Incorrect inclusion ineligible patient34

Outcome measures

PrimaryTime to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms (ARVI, Confirmed by Polymerase Chain Reaction (PCR)).

Outcome Measure is evaluated on the basis of ARVI, confirmed by Polymerase chain reaction (PCR), i.e virus detection. ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from "0" to "42". The TSS higher score is the worse outcome.

Time frame:
14 days of observation
Reported as:
Mean · day
Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms (ARVI, Confirmed by Polymerase Chain Reaction (PCR)).
dayRaphaminPlacebo
Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms (ARVI, Confirmed by Polymerase Chain Reaction (PCR)).3.3 ± 1.74.4 ± 2.6
Statistical analysis
  • Raphamin vs Placebo · t-test, 2 sided · p = 0.0003 · Mean difference (final values): 1.09 · 95% CI 0.51 to 1.67
SecondarySeverity of ARVI (Clinically Diagnosed and/or PCR-confirmed).

The outcome measure is based on the area under the curve (AUC) for the TSS (Total symptoms score). TSS is calculated as a sum of scores for 14 different symptoms. 13 of them are different ARVI manifestations, each of them is evaluated on a scale: 0 (none), 1 (mild), 2 (moderate), 3 (severe). 14th symptom is body temperature (temp) which is converted to its score using following rules: if temp \<= 37.3 then score = 0 (none) if 37.3 \< temp \<= 38.0 then score = 1 (mild) if 38.0 \< temp \<= 39.0 then score = 2 (moderate) if 39.0 \< temp then score = 3 (severe) So it is 14 symptoms and the score for each of them varies between 0 and 3. Minimum TSS is 0, maximum is 42 (higher TSS score is worse). AUC is calculated for all timepoints available for patient.

Time frame:
Day1 through Day6 of the treatment and observation
Reported as:
Mean · scores on a scale*days
Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed).
scores on a scale*daysRaphaminPlacebo
Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed), AUC score44.6 ± 23.846.9 ± 24.3
Severity of ARVI (PCR-confirmed), AUC score48.3 ± 25.253.6 ± 25.6
Statistical analysis
  • Raphamin vs Placebo · t-test, 2 sided · p = 0.3274 · Mean difference (final values): 2.35 · 95% CI -2.36 to 7.06
  • Raphamin vs Placebo · t-test, 2 sided · p = 0.1171 · Mean difference (final values): 5.30 · 95% CI -1.34 to 11.93
SecondaryPercentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed).

ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from "0" to "42". The TSS higher score is the worse outcome.

Time frame:
14 days of observation
Reported as:
Count of participants · Participants
Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed).
ParticipantsRaphaminPlacebo
Day 22416
Day 36446
Day 49694
Day 5149136
Day 6174162
Day 7191181
Statistical analysis
  • Raphamin vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001
SecondaryTime to Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed).

ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from "0" to "42". The TSS higher score is the worse outcome.

Time frame:
14 days of observation
Reported as:
Mean · day
Time to Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed).
dayRaphaminPlacebo
Time to Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed).3.4 ± 1.83.9 ± 2.4
Statistical analysis
  • Raphamin vs Placebo · t-test, 2 sided · p = 0.0073 · Mean difference (final values): 0.58 · 95% CI 0.16 to 1.00
SecondaryPercentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed).

Outcome Measure is based on the Percentage of Patients With Resolution of ARVI, confirmed by Polymerase chain reaction (PCR), i.e virus detection. ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from "0" to "42". The TSS higher score is the worse outcome.

Time frame:
14 days of observation
Reported as:
Count of participants · Participants
Percentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed).
ParticipantsRaphaminPlacebo
Day 2164
Day 33616
Day 45939
Day 59564
Day 610777
Day 711989
Statistical analysis
  • Raphamin vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001
SecondaryDosing Frequency of Antipyretics.

Outcome Measure is based on the rates of antipyretic use per patient during days 1 to 3 of therapy according to the electronic patient diary.

Time frame:
3 days of therapy
Reported as:
Mean · number of doses
Dosing Frequency of Antipyretics.
number of dosesRaphaminPlacebo
Day 10.43 ± 0.720.39 ± 0.72
Day 20.22 ± 0.610.25 ± 0.66
Day 30.09 ± 0.380.07 ± 0.31
Statistical analysis
  • Raphamin vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.3627
  • Raphamin vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.5578
  • Raphamin vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.7688
SecondaryPercentage of Patients Reporting Worsening of Illness.

Outcome Measure is based on the rates of Complications that require the use of antibiotics or hospitalization.

Time frame:
Day 4 through day 14 of the treatment and observation period
Reported as:
Count of participants · Participants
Percentage of Patients Reporting Worsening of Illness.
ParticipantsRaphaminPlacebo
Percentage of Patients Reporting Worsening of Illness.10
Statistical analysis
  • Raphamin vs Placebo · Fisher Exact · p = 0.4926
SecondaryOccurrence and Type of Adverse Events (AE) During the Treatment. AE Severity.

1. The intensity (severity) of adverse events. 2. Causal relationship of AEs to the sudy drug. 3. Outcome of AEs. Based on medical records.

Time frame:
14 days of observation
Reported as:
Number · number of cases
Occurrence and Type of Adverse Events (AE) During the Treatment. AE Severity.
number of casesRaphaminPlacebo
Severity/Mild26
Severity/Moderate50
Causal relationship/Not connected76
Outcome/Recovery65
Outcome/Unknown11
Statistical analysis
  • Raphamin vs Placebo · Fisher Exact · p = 0.021
  • Raphamin vs Placebo · Fisher Exact · p = 1.00
SecondaryChanges in Vital Signs: Pulse Rate/Heart Rate in Beats Per Minute (Bpm).

The outcome measure is based on the medical records. The patient's heart rate (heart rate) is measured by the physician in every visit (on days 1, 5, and 7).

Time frame:
Day 1 through day 7 of the treatment and observation period.
Reported as:
Mean · beats per minute
Changes in Vital Signs: Pulse Rate/Heart Rate in Beats Per Minute (Bpm).
beats per minuteRaphaminPlacebo
Visit 187.1 ± 11.487.2 ± 10.6
Visit 277.9 ± 7.178.1 ± 7.2
Visit 376.3 ± 7.076.7 ± 6.8
Statistical analysis
  • Raphamin vs Placebo · Median test · p = 0.7848
  • Raphamin vs Placebo · Median test · p = 0.9596
  • Raphamin vs Placebo · Median test · p = 0.6902
SecondaryChanges in Vital Signs: Respiration Rate/Breathing Rate in Breaths Per Minute.

Outcome Measure is based on the medical records. The patient's respiration rate (breathing rate) is measured by physician in every visit (on days 1, 5, and 7).

Time frame:
Day 1 through day 7 of the treatment and observation period.
Reported as:
Mean · breaths per minute
Changes in Vital Signs: Respiration Rate/Breathing Rate in Breaths Per Minute.
breaths per minuteRaphaminPlacebo
Visit 120.8 ± 3.320.7 ± 2.8
Visit 218.4 ± 1.918.6 ± 1.7
Visit 318.0 ± 1.718.2 ± 1.7
Statistical analysis
  • Raphamin vs Placebo · Median test · p = 0.3266
  • Raphamin vs Placebo · Median test · p = 0.0930
  • Raphamin vs Placebo · Median test · p = 0.2308
SecondaryChanges in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg).

Outcome Measure is based on the medical records. The patient's blood pressure is measured by the physician in every visit (on days 1, 5, and 7).

Time frame:
Day 1 through day 7 of the treatment and observation period.
Reported as:
Mean · mmHg
Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg).
mmHgRaphaminPlacebo
Visit 1/Systolic blood pressure112 ± 9.9112 ± 8.9
Visit 2/Systolic blood pressure111 ± 9.8112 ± 8.7
Visit 3/Systolic blood pressure111 ± 10.2111 ± 9.4
Visit 1/Diastolic blood pressure70.0 ± 5.769.8 ± 5.8
Visit 2/Diastolic blood pressure69.7 ± 5.769.5 ± 5.4
Visit 3/Diastolic blood pressure69.6 ± 5.769.4 ± 5.9
Statistical analysis
  • Raphamin vs Placebo · Median test · p = 0.6610
  • Raphamin vs Placebo · Median test · p = 0.4884
  • Raphamin vs Placebo · Median test · p = 0.3494
  • Raphamin vs Placebo · Median test · p = 0.9531
  • Raphamin vs Placebo · Median test · p = 0.5506
  • Raphamin vs Placebo · Median test · p = 0.8259
SecondaryPercentage of Patients With Clinically Relevant Abnormal Laboratory Findings.

Outcome Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which are beyond the reference values at the end of treatment.

Time frame:
Day 1 through day 7 of the treatment and observation period.
Reported as:
Count of participants · Participants
Percentage of Patients With Clinically Relevant Abnormal Laboratory Findings.
ParticipantsRaphaminPlacebo
Percentage of Patients With Clinically Relevant Abnormal Laboratory Findings.10
Statistical analysis
  • Raphamin vs Placebo · Fisher Exact · p = 0.49

Adverse events

Collected over Registration of AEs begins after the first dose of study drug and continues throughout the entire period of study therapy - 14 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Raphamin0/206 (0%)1/206 (0.5%)6/206 (2.9%)
Placebo0/214 (0%)0/214 (0%)5/214 (2.3%)
Most frequent serious events
Most frequent serious events
EventRaphaminPlacebo
Worsening fluInfections and infestations1/2060/214
Most frequent other events
Showing 10 of 12
Most frequent other events
EventRaphaminPlacebo
Bacterial superinfectionInfections and infestations1/2060/214
Viral upper respiratory tract infectionInfections and infestations1/2060/214
Increased percentage of monocytesInvestigations1/2060/214
DizzinessNervous system disorders1/2060/214
Loss of consciousnessNervous system disorders1/2060/214
PallorVascular disorders1/2060/214
FluInfections and infestations1/2061/214
AdenoiditisInfections and infestations0/2061/214
Coronavirus infection COVID-19Infections and infestations0/2061/214
EpistaxisRespiratory, thoracic and mediastinal disorders0/2061/214

Baseline characteristics

Age, Continuous
Age, Continuous(years)RaphaminPlaceboTotal
Mean14.3 ± 1.714.2 ± 1.714.2 ± 1.7
Age, Customized
Age, Customized(Participants)RaphaminPlaceboTotal
12 to 18 years199205404
Sex: Female, Male
Sex: Female, Male(Participants)RaphaminPlaceboTotal
Female100107207
Male9998197
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)RaphaminPlaceboTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)RaphaminPlaceboTotal
Russia199205404
08

Study locations

29 sites
  • LLC "European Medical Center "UMMC-Health"
    Ekaterinburg, 620144, Russian Federation
  • Kazan State Medical University
    Kazan, 420012, Russian Federation
  • Llc "Medlight"
    Kazan, 420097, Russian Federation
  • Specialized Clinical Hospital for Infectious Diseases
    Krasnodar, 350015, Russian Federation
  • Llc "Olla-Med"
    Moscow, 105554, Russian Federation
  • Russian National Research Medical University named after N.I. Pirogov
    Moscow, 117997, Russian Federation
  • Morozovskaya Children's City Clinical Hospital of the Moscow Department of Health
    Moscow, 119049, Russian Federation
  • Federal Scientific and Clinical Center for Physical and Chemical Medicine of the Federal Medical and Biological Agency
    Moscow, 119435, Russian Federation
  • Llc "Diagnostics and Vaccines"
    Moscow, 129515, Russian Federation
  • Novosibirsk State Medical University
    Novosibirsk, 630091, Russian Federation
  • City Children's Clinical Polyclinic # 5
    Perm, 614066, Russian Federation
  • LLC "Professorial Clinic"
    Perm, 614070, Russian Federation
  • Clinical and diagnostic center "Health" of the city of Rostov-on-Don
    Rostov-on-Don, 344011, Russian Federation
  • Children's City Hospital #1 of Rostov-on-Don city
    Rostov-on-Don, 344019, Russian Federation
  • Rostov State Medical University
    Rostov-on-Don, 344022, Russian Federation
  • Ryazan State Medical University named after academician I.P. Pavlov
    Ryazan, 390026, Russian Federation
  • Children's city polyclinic # 44
    Saint Petersburg, 191144, Russian Federation
  • LLC "Energy of health"
    Saint Petersburg, 194156, Russian Federation
  • Children's city polyclinic # 35
    Saint Petersburg, 196191, Russian Federation
  • Research Institute of Influenza named after A.A. Smorodintsev
    Saint Petersburg, 197376, Russian Federation
  • Samara Regional Children's Clinical Hospital named after N.N. Ivanova
    Samara, 443079, Russian Federation
  • National Research Mordovian State University named after N.P. Ogarev
    Saransk, 430005, Russian Federation
  • LLC "DNA Research Center"
    Saratov, 410005, Russian Federation
  • Smolensk State Medical University
    Smolensk, 214019, Russian Federation
  • Bashkir State Medical University/Department of Outpatient and Emergency Pediatrics
    Ufa, 450008, Russian Federation
  • Volgograd State Medical University/Department of Pediatrics and Neonatology
    Volgograd, 400131, Russian Federation
  • Yaroslavl State Medical University/Department of Pediatrics IPGE
    Yaroslavl, 150000, Russian Federation
  • Yaroslavl State Medical University/Department of Pediatrics № 2
    Yaroslavl, 150000, Russian Federation
  • Clinical Hospital # 2
    Yaroslavl, 150030, Russian Federation
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Jul 2023, 26 months.

Results were first posted in Oct 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2021
First posted
Jun 9, 2021
StartActual
Apr 29, 2021
Primary completionActual
Jul 21, 2023
CompletionActual
Jul 21, 2023
Results first posted
Oct 15, 2024
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04918771
Responsible party
Sponsor
First posted
Jun 9, 2021
Start date
Apr 29, 2021
Primary completion
Jul 21, 2023
Completion
Jul 21, 2023
Results posted
Oct 15, 2024
Last update
Oct 15, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MMH-407

Start the discussion